

# A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

NCT06993480

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Ausper Biopharma Co., Ltd.
Enrollment	30 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Voluntarily participated in the study and signed an informed consent form;
- Aged between 18 and 55 years at the time of signing the informed consent form;
- Body mass index (BMI) within the range of 18-30 kg/ m<sup>2</sup>;
- HBeAg negative or positive at screening;
- HBsAg or HBV DNA positive for at least 6 months;

... and 4 more (see full listing online)

### Exclusion (21)

- Clinically significant abnormalities other than a history of CHB infection;
- Concomitant clinically significant other liver diseases;
- Any serious infection other than CHB infection requiring intravenous anti-infective therapy within 1 month prior to screening;
- Active hepatitis C, Human immunodeficiency virus (HIV) positive, syphilis positive;
- Liver stiffness value (LSM)  $\gt$  9.0 kPa at screening;

... and 16 more (see full listing online)

## Locations (1 total)

---

The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China